Key result
Donor platelet concentrate transfusion after cardiopulmonary bypass is unnecessary for prevention in CAD patients on aspirin, as hemostatic potential in plasma was preserved.
Why the study?
Does donor platelet concentrate transfusion improve hemostatic parameters in CAD patients on prolonged aspirin therapy undergoing on-pump CABG?
RCT (n=148)
randomly
Does donor platelet concentrate transfusion improve hemostatic parameters in CAD patients on prolonged aspirin therapy undergoing on-pump CABG?
Routine prophylactic platelet transfusion is unnecessary in patients on prolonged aspirin therapy undergoing on-pump CABG, as endogenous hemostatic potential remains preserved.
To evaluate the parameters of the thrombin generation test (TGT) in coronary artery disease (CAD) patients on prolonged aspirin therapy during on-pump coronary artery bypass grafting (CABG) after donor platelet concentrate transfusion. A total of 148 patients with CAD on prolonged aspirin therapy (75-100 mg/day) who have undergone elective on-pump CABG were consecutively included in the study. Patients were divided randomly into two groups. Group 1 (n = 76) received donor platelet transfusions after cardiopulmonary bypass, whereas Group 2 (n = 72) did not. TGT parameters were measured using an analyzer at pre-, intra-, and early postoperative periods. Activation of the endogenous thrombin potential was observed in patients on prolonged aspirin therapy in the pre- and intraoperative periods, as confirmed by high peak thrombin and increased velocity index. The activation time of the prothrombinase complex and thrombin generation time were greater than the control group. The blood hemostatic potential in patients who did not receive transfusions in the early postoperative period decreased up to the level of the control group in the extended time parameters. Hemostatic potential in plasma in patients on aspirin was preserved. Given the laboratory test results and clinical data, platelet concentrate transfusion is unnecessary for prevention.
No takes yet. Share an insight, caveat, or question.
Груздева et al. (2017) conducted an RCT in Coronary artery disease (CAD) (n=148). Donor platelet concentrate transfusion vs. No donor platelet transfusion was evaluated on Thrombin generation test (TGT) parameters. Donor platelet concentrate transfusion after cardiopulmonary bypass is unnecessary for prevention in CAD patients on aspirin, as hemostatic potential in plasma was preserved.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: